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Abstract
Introduction: It is well-known that specific foods trigger migraine attacks in some patients. We aimed to investigate the
effect of diet restriction, based on IgG antibodies against food antigens on the course of migraine attacks in this
randomised, double blind, cross-over, headache-diary based trial on 30 patients diagnosed with migraine without aura.
Methods: Following a 6-week baseline, IgG antibodies against 266 food antigens were detected by ELISA. Then, the
patients were randomised to a 6-week diet either excluding or including specific foods with raised IgG antibodies,
individually. Following a 2-week diet-free interval after the first diet period, the same patients were given the opposite
6-week diet (provocation diet following elimination diet or vice versa). Patients and their physicians were blinded to IgG
test results and the type of diet (provocation or elimination). Primary parameters were number of headache days and
migraine attack count. Of 30 patients, 28 were female and 2 were male, aged 19–52 years (mean, 35 10 years).
Results: The average count of reactions with abnormally high titre was 24 11 against 266 foods. Compared to baseline,
there was a statistically significant reduction in the number of headache days (from 10.5 4.4 to 7.5 3.7; P<0.001) and
number of migraine attacks (from 9.0 4.4 to 6.2 3.8; P<0.001) in the elimination diet period.
Conclusion: This is the first randomised, cross-over study in migraineurs, showing that diet restriction based on IgG
antibodies is an effective strategy in reducing the frequency of migraine attacks.
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Introduction
The exact pathophysiology of migraine is still unclear.
Besides diﬀerent genetic mutations, there is evidence of
a profound role of meningeal inﬂammation in migraine
pathogenesis (1,2). Environmental trigger factors are
thought to play an important role. Many contributing
factors may trigger the occurrence of migraine attacks
and food is one of the most well-known (3–8). These,
however, as with most elements of migraine, need to be
individualised to the patient with migraine.
Since the 1930s, hidden food allergy has been sus-
pected to be linked to migraine. Several studies showed
signiﬁcant improvement when patients were put on an
elimination diet (9–14). IgE-speciﬁc food allergy has
been shown to be related with migraine supported by
the success of individualised diet in controlling migraine
attacks (4,15). Non-IgE antibody mediated mechanisms
have also been proposed in food allergy (16). Aljada
et al. (17) provided evidence for the pro-inﬂammatory
eﬀect of food intake. IgG antibodies against food anti-
genshavebeenfoundtobecorrelatedwithinﬂammation
and intima media thickness in obese juveniles (18).
Several studies reported signiﬁcant improvement in irri-
table bowel syndrome (IBS) by food elimination based
on IgG antibodies against to food antigens (19–22).
Rees et al. (23) showed a beneﬁcial eﬀect of a diet
guided by IgG antibodies to food in migraine patients.
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liminary evidence that IgG-based elimination diets suc-
cessfully controlled the migraine without need of
medication.
Some foods (such as cheese, chocolate or wine) are
thought to be one of the well-known reasons triggering
of migraine attacks according to consistent reports
from the patients. It has been reported that diet with
low-fat intake could reduce the headache frequency and
intensity (25). On the other hand, some additives (such
as triclorogalactosucrose or aspartame) may trigger
attacks in some migraineurs (4,26–29). However, it is
neither easy nor very useful to organise routine diet
according to robust protocols for many patients
(3,30). All this indicates that there is a need for an
individualised approach of the diet to relieve migraine.
One has to distinguish between inﬂammation-induced
migraine and migraine caused by food via other
mechanisms such as histamine-induced vasodilatation.
IgG could be one of the markers to identify food
which causes inﬂammation and could cause migraine
attacks in predisposed individuals.
In this study, we aimed to test the beneﬁcial eﬀect of
diet based on speciﬁc total IgG antibodies (subclasses
1–4) against 266 food antigens in controlling migraine




This study was designed as a double-blind, randomised,
controlled, cross-over clinical trial (31). After the
approval of the hospital ethics committee, patients
giving their written informed consent were recruited
from headache out-patient clinic with the diagnosis of
migraine without aura according to the criteria of the
International Classiﬁcation of Headache Disorders,
2nd edition (32). For inclusion in the study, the patients
should: (i) have had at least 4 attacks and 4 headache
days per month within the last months; (ii) be aged
18–55 years; (iii) be treated with acute attack medica-
tions only or with preventive medications unchanged at
least for 3 months; and (iv) be able to understand and
co-operate with the needs of the study and the diet. The
patients with suspected or clear-cut medication overuse,
pure menstrual migraine or any other associated head-
ache disorder were excluded.
The study consisted of three main phases – baseline
phase, ﬁrst diet phase and second diet phase (Figure 1).
In all phases, patients were asked not to change the
dosages of their preventive medications if they were
using any. The patients visited the same headache physi-
cian (ﬁrst author, blinded to antibody test results and the
order of the patient’s diet phases) during the whole study.
Attheﬁrstvisit(Visit-1),theeligiblepatientsrecruitedfor
the study were evaluated and asked to complete a head-
ache diary for 6 weeks. The diary included headache
attack frequency, headache days, attack duration in
hours, attack severity in visual analogue scale (VAS)
and medication information. During this 6-week baseline
phase, the patients were followed in their usual daily diet.
At the second visit (Visit-2) at the end of this 6-week base-
line phase, the patients returned their diaries for evalua-
tion and gave venous blood samples for detection of IgG
antibodies against 266 food antigens (see Appendix 1)
as described below. Then, the patients were allocated to
one of the two 6-week diets based on a randomisation
schedule either excluding (elimination diet) or including
(provocation diet) speciﬁc foods with abnormally raised
IgG antibodies, as described below. They were also asked
to ﬁll in a headache diary for 6 weeks. In this ‘ﬁrst diet
phase’, half of the patients were randomised to elimina-
tion diet and other half maintained provocation diet for 6
weeks. Neither the patients nor the headache physician
knew if the diet was for elimination or provocation as
well as IgG antibody test results. At the third visit
(Visit-3) at the end of the ‘ﬁrst diet phase’, the patients
returned their diaries for evaluation. Then, the patients
were allowed to return to their usual diets for 2 weeks
without keeping diary. In ‘second diet phase’ following
this 2-week diet-free interval, the patients who were on
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Figure 1. Cross-over design of the study.
830 Cephalalgia 30(7)provocation diet for 6 weeks and vice versa. They were
asked to ﬁll a headache diary for 6 weeks during the
second diet phase. At the fourth visit (Visit-4) following
the ‘second diet phase’, diaries were recollected and the
diet codes were broken. Patients were informed about
their results and the order of the types of their diets.
IgG antibody detection against food antigens
IgG antibodies against 266 food antigens were detected
using a commercially available enzyme linked immuno-
sorbant assay (ELISA) test (ImuPro 300 test; Evomed/
R-Biopharm AG, Darmstadt, Germany), previously
used by Wilders-Truschnig et al. (18) IgG calibration
was performed against the international reference mate-
rial 1st WHO IRP 67/86 for human IgG. Quantitative
measurements are reported in mg/l. Detection limit was
2.5g/l, normalised cut-oﬀ value was 7.5mg/l, according
to the validation protocol provided by the manufac-
turer. All values above 7.5mg/l were considered as pos-
itive reaction to the corresponding food. Positive
reaction was graded as: ‘low’ for titres between 7.50–
12.50mg/l; ‘moderate’ for 12.51–20mg/l; ‘high’ for
20.1–50mg/l; and ‘very high’ for 50.1–200mg/l. Since
IgG antibodies against food disappear within 3 months
to 2 years depending upon initial titre, antibody detec-
tion was not repeated after the diet phases which were
not long enough to see any change in antibody titres.
Diet preparation
Diets were arranged according to the IgG antibody
results; eating habits for individual patients were
taken into account and patients were educated about
keeping diet by a dietician (DKU, co-author). Diets
were assembled by this dietician, trying to oﬀer a nutri-
tionally balanced diet. The elimination diet consisted of
a deﬁned panel of IgG-negative food, while the provo-
cation diet consisted in a panel of IgG-positive food
and IgG-negative food necessary to comply with a
balanced diet. Both elimination diet and provocation
diet did not diﬀer in calorie content. Patients were
not allowed to eat any other food as speciﬁed by the
dietician. In both diet phases, patients were never
forced to eat or avoid from certain foods to protect
the blindness of patients and their physician for the
type of diet phase (elimination or provocation).
Instead, they were asked to follow their specially
arranged diet list exactly and not to consume any
other food in any diet phase.
Statistical analysis
The primary parameters used for comparisons were
number of headache days, migraine attack count,
mean attack duration, median attack severity (in VAS
score from 0–10), number of migraine attacks with
acute medication and total medication intake within
6-week periods of each three phases. Statistical analyses
included parametric tests to compare means (paired
and unpaired two sample t-test), non-parametric tests
to compare medians (Wilcoxon test and Mann–
Whitney test) and 2 2 chi-square test. For compari-
sons between baseline phase and provocation phase or
between baseline phase and elimination phase or
between provocation phase and elimination phase,
both paired t-tests (parametric test and Wilcoxon
signed test as non-parametric test) were used. For com-
parisons between patients whose ﬁrst diet phase was
elimination diet and patients whose second diet phase
was elimination diet (to test the ‘period eﬀect’), both
unpaired t-tests (parametric test and Mann–Whitney
unpaired test as a non-parametric test) were used.
Results
A total of 35 patients were recruited for the study. In
the baseline phase and the ﬁrst diet phase, ﬁve patients
withdrew from the study for diﬀerent reasons, such as
moving to another city, unwillingness to maintain diet
or skipping the visit. The remaining 30 patients fully
completed the study. Of these 30 patients, 28 were
females and 2 were males. Ages varied from 19 years
to 52 years (mean, 35 10 years). Their mean migraine
duration was 13 9 years (range, 1–30 years). All 30
patients were using acute attack medication for
migraine attacks and 15 were also using preventive
medication. From the IgG antibody tests against to
266 food allergens, mean reaction (abnormally high
titre) count was 24 11 (7–47 reactions in individual
patients). Of the total 732 reactions, 297 (40%) were
low, 337 (46%) were moderate, 70 (10%) were high and
28 (4%) were very high graded. The food categories are
listed in Table 1 from the most frequent IgG positivity
to least.
The parameters of headache and medication are
shown in Tables 2 and 3. In the elimination diet
period compared to both baseline period and provoca-
tion diet period, there was a statistically signiﬁcant
reduction in attack count, number of headache days,
number of attacks with acute medication and total
medication intake whilst no signiﬁcant change occurred
between the provocation diet period and the baseline
period (Table 2). However, attack severity and attack
duration did not change signiﬁcantly between all three
phases (Table 2). By comparing percentage diﬀerences
from baseline, in the elimination diet period, attack
count, number of headache days, number of attacks
with acute medication and total medication intake
showed signiﬁcant reduction compared to the
Alpay et al. 831provocation diet period (Table 3). To test the eﬀect of
order of diet, patients were divided to two subgroups:
15 patients with elimination diet in the ‘ﬁrst diet phase’
and 15 patients with elimination diet in the ‘second diet
phase’. We calculated the diﬀerences (in both real num-
bers and percentage diﬀerences) between the elimina-
tion diet period and the baseline, provocation diet
period and baseline and elimination diet period and
provocation diet period for attack count, number of
headache days, number of attack with acute medica-
tion, total medication intake, median attack severity
and mean attack duration for each subgroup. In none
of these parameters, did the two subgroups show any
signiﬁcant diﬀerence in any of these comparisons,
indicating that, whether the elimination diet was in
the ﬁrst diet phase or second diet phase, the order of
elimination diet period had no signiﬁcant eﬀect on the
outcome (Table 4). Similar calculations were made for
preventive medicine usage and there was no signiﬁcant
change in any parameters between preventive medicine
users (n¼15) and non-users (n¼15).
We also calculated if the patient showed at least a
30% reduction and at least a 50% reduction for attack
count and number of headache days using elimination
diet compared to provocation diet and to the baseline
period. In comparison between elimination and base-
line phases, for parameters of the number of headache
days and attack count, reduction was  30% in 16
(53%) and 16 (53%) patients, respectively, and reduc-
tion was  50% in 7 (23%) and 6 (20%) patients,
respectively. In comparison between elimination and
provocation phases, for the number of headache days
and attack count, reduction was  30% in 15 (50%) and
12 (40%) patients, respectively, and reduction was
 50% in 6 (20%) and 4 (13%) patients, respectively.
Discussion
The concept that food may trigger some symptoms
creates an increasing pressure on the healthcare
system to investigate possible causal relationships
between food intake and speciﬁc diseases. In the case
of migraine, it seems evident that food is not the pri-
mary cause but, via diﬀerent mechanisms, is able to
induce or aggravate migraine attacks. In some indivi-
duals, the consumption of chocolate or red wine is
enough to provoke an attack; whereas, in others, a
combination of food is required, even sometimes with
food which has never been related to migraine for other
migraineurs. However, it is neither easy nor very useful
to organise routine diet according to robust protocols
for many patients (3,30). All this indicates that there is
a need for an individualised approach to diet to relieve
migraine.
Table 2. Headache and medication parameters during study phases
Phases, each of 6 weeks SD (95% CI lower; upper limits)
Parameters Baseline Provocation diet Elimination diet
Attack count 8.97 4.4 (7.32; 10.61) 8.13 4.6 (6.43; 9.83) *6.17 3.8 (4.67; 7.58)
Number of headache days 10.53 4.4 (8.90; 12.17) 10.20 5.5 (8.15; 12.25) *7.47 3.7 (6.08; 8.85)
Number of attacks with acute medication 6.73 2.9 (5.65; 7.81) 6.53 4.0 (5.05; 8.01)
y4.90 3.2 (3.69; 6.11)
Total medication intake (tablets) 11.37 7.4 (8.61; 14.13) 10.57 7.7 (7.69; 13.44)
z7.77 5.7 (5.65; 9.89)
Median attack severity (VAS) 6.02 1.6 (5.42; 6.62) 6.07 1.6 (5.47; 6.66) 6.07 1.6 (5.60; 6.77)
Mean attack duration (hours) 11.39 5.6 (9.30; 13.48) 12.53 6.7 (10.04; 15.03) 12.53 6.7 (9.57; 15.14)
*P<0.001/P<0.001;
yP<0.001/P¼0.001;
zP¼0.002/P¼0.001 in Paired t-test/Wilcoxon signed test (with 95% confidence intervals) comparing
elimination and baseline diet phases (differences are statistically significant).






















832 Cephalalgia 30(7)A recent study addressed a relationship between IgG
antibodies against food antigens and systemic inﬂam-
mation measured by C-reactive protein (CRP) in obese
juvenile patients (18). Obesity was also shown as an
important risk factor in the development of chronic
daily headache and chronic migraine (33,34). The ther-
apeutic potential of dietary elimination on the basis of
the presence of IgG antibodies against food in patients
with IBS has been investigated. Patients were rando-
mised to receive either a diet excluding all foods to
which they had raised IgG antibodies or a sham diet
excluding the same number of foods but not those to
which they had antibodies (19). The true diet resulted
in a statistically signiﬁcant reduction in symptom
scores compared to the sham diet and the authors con-
cluded that this technique is worthy of further clinical
research in IBS.
There is growing evidence that inﬂammation plays
an important role in the pathogenesis of migraine (2).
The calcitonin gene-related peptide (CGRP), and nitric
oxide (NO) may participate in immune and inﬂamma-
tory responses. Some patients report that certain foods
only trigger migraine in conjunction with stress or
extended physical exercise. Both conditions, recognised
as triggers of migraine, cause the release of pro-
inﬂammatory cytokines. In these cases, inﬂammation
caused by food could create the pro-inﬂammatory
milieu necessary for the induction of migraine by
other triggers. If we focus on inﬂammation induced
by food, a speciﬁc marker is needed. All IgG subclasses,
except IgG4 lead to an inﬂammatory response when in
contact with the respective antigen. Determination of
speciﬁc IgG to a large number of foods is an ideal tool
to detect individually suspected food and enables a
modiﬁcation of nutritional habits in order to prevent
chronic inﬂammation and onset of migraine in sensi-
tised patients. Susceptibility to other triggers such as
histamine, caused by impaired detoxiﬁcation by low
Table 4. Percentage difference of elimination diet parameters from baseline period between the groups starting with
















Attack count  37.5 ( 55.6;  20.0)  30.0 ( 35.0;  16.7) NS (P¼0.367)
Number of headache days  30.0 ( 50.0; 0.0)  33.3 ( 46.2; 0.0) NS (P¼0.902)
Number of attacks with acute medication  37.5 ( 55.6; 0.0)  30.0 ( 50.0; 0.0) NS (P¼0.653)
Total medication intake (tablets)  25.0 ( 65.2; 20.0)  18.2 ( 37.9; 0.0) NS (P¼0.539)
Median attack severity (VAS) 0.0 (0.0; 14.3) 0.0 ( 20.0; 14.3) NS (P¼0.512)
Mean attack duration (h) 10.9 ( 29.0; 74.9) 3.7 ( 27.3; 13.0) NS (P¼0.267)
*Patients starting with elimination diet; **patients starting with provocation diet;
y percentage difference from baseline period;
z(25%; 75%) percentiles.
NS, not significant in Mann-Whitney test with 95% confidence interval.

















Attack count  7.81 37.6 ( 21.85; 6.23)  29.11 26.0 ( 38.83;  19.39) P¼0.006/0.004
Number of headache days  2.77 35.2 ( 15.93; 10.38)  25.68 30.9 ( 37.22;  14.13) P¼0.006/0.006
Number of attacks
with acute medication
3.49 66.4 ( 21.30; 28.29)  20.50 54.2 ( 40.74;  0.27) P¼0.006/0.002
Total medication intake (tablets) 7.34 67.0 ( 17.68; 32.35)  16.33 56.6 ( 37.41; 4.75) P¼0.006/0.006
Median attack severity (VAS) 5.12 33.3 ( 7.33; 17.56) 8.15 42.0 ( 7.53; 23.82) NS (P¼0.348/0.460)
Mean attack duration (h) 25.19 81.6 ( 5.29; 55.67) 12.79 53.3 ( 7.10; 32.68) NS (P¼0.442/0.738)
*Percentage difference from baseline period;
y(lower; upper) limits of 95% confidence interval;
zP-values with 95% confidence interval;
NS, not significant.
Alpay et al. 833activity of di-amino-oxidase, may play an additional
role and could be considered in the proposed diet.
A recent study from Mexico investigated 56 patients
with recurrent attacks of migraine (at least once a
month) and 56 control subjects without migraine and
measured their allergen-speciﬁc IgG against 108 food
allergens by enzyme immunoassay (24). The authors
reported that there was a statistically signiﬁcant diﬀer-
ence in the number of positive results for IgG food aller-
gens between patients and controls and the elimination
diet successfully controls the migraine without need of
medication. As distinct from this study, we used a ran-
domised, cross-over design with clear deﬁnition of diag-
nosticandfollow-upcriteriaandstudyset-up.Weuseda
baseline period and provocative diet periods to compare
elimination diet period of the same individuals as their
own controls instead of using other healthy volunteers.
Our data conﬁrm the importance of determination
of speciﬁc IgG antibodies against food antigens for pre-
vention and cure of food-induced migraine attacks,
leading to lower drug consumption, fewer adverse
drug reactions and fewer days with migraine.
Conclusions
Diet restriction based on IgG antibodies might be
an eﬀective strategy in reducing the frequency of
migraine attacks and could be implemented for
therapy-resistant patient. However, because of the
small sample size of this study, caution is required
while translating these results into daily practice.
Further research is also needed to determine the mech-
anism of IgG positive, food-induced migraine and its
relation to other triggers.
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Appendix 1
Full list of 266 food allergens tested
Milk
Milk (cow)
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